作者研究了新抗聚集制剂噻氯匹定对糖尿病性微血管病变病人止血系统的作用。初步认为,本品可刺激PGE_1、PGD_2以及内源性抗聚集剂前列环素的合成,其抗聚集作用优于阿司匹林、磺吡唑酮和潘生丁。将97例糖尿病人,分为三组,第一组30例,使用本品250mg每日2次,共1个月。第二组32例,使用本品250 mg每日2次,共6个月。第三组为对照组,35例病人,仅用降糖剂。所有三组病人,均根据糖尿病类型 The authors investigated the effect of the new anti-aggregation agent ticlopidine on the hemostatic system in patients with diabetic microangiopathy. Preliminary believe that this product can stimulate PGE_1, PGD_2 and endogenous anti-aggregating agent prostacyclin synthesis, its anti-aggregation effect is better than aspirin, pyrazolone and dipyridamole. 97 cases of diabetic patients were divided into three groups, the first group of 30 cases, the FDA 250mg twice daily for a total of 1 month. The second group of 32 cases, the use of this product 250 mg twice daily for a total of 6 months. The third group for the control group, 35 patients, only hypoglycemic agents. All three groups of patients were based on type of diabetes